alogliptin articles & resources on Made-in-China.com

Japan-Based Takeda Pharma Has Received Positive CHMP Opinion

Jul 30, 2013

Japan-based Takeda Pharma has received positive CHMP opinion for its three new type 2 diabetes therapies from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The therapies include Vipidia ...

Tags: Therapies, CHMP Opinion

Takeda Has Received FDA Approval for Three New Type 2 Diabetes Therapies Nesina

Jan 30, 2013

Takeda Pharmaceutical has received FDA approval for three new type 2 diabetes therapies Nesina (alogliptin) and fixed-dose combinations Oseni (alogliptin and pioglitazone) and Kazano (alogliptin and metformin HCl). Takeda expects to ...

Tags: FDA, diabetes therapies, Pharmaceuticals

Takeda Global Research & Development Center Has Resubmitted New Drug Applications

Dec 5, 2012

Furiex Pharmaceuticals said Takeda Global Research & Development Center has resubmitted New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone ...

Tags: Furiex Pharmaceuticals, NDAs, alogliptin and pioglitazone

Takeda Receives Response From FDA Regarding Its New Drug Applications

Dec 4, 2012

Takeda Pharmaceutical has received a complete response letter from the US Food and Drug Administration (FDA) regarding its new drug applications (NDAs) for alogliptin and the fixed-dose combination therapy alogliptin and pioglitazone. ...

Tags: FDA, alogliptin, clinical trial program

alogliptin

Japan-Based Takeda Pharma Has Received Positive CHMP Opinion

Takeda Has Received FDA Approval for Three New Type 2 Diabetes Therapies Nesina

Takeda Global Research & Development Center Has Resubmitted New Drug Applications

Takeda Receives Response From FDA Regarding Its New Drug Applications

Related Products